JCO global oncology · 2025
Nationwide Insights on Immunotherapy in a Low- and Middle-Income Country: Armenia's Struggle for Equitable Cancer Care in an Out-of-Pocket System.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sargsyan Amalya, Tamamyan Gevorg, Oganisian Arman, Zohrabyan Davit, Safaryan Liana, Avagyan Armen, Harutyunayn Lilit, Sargsyan Mariam, Harutyunyan Martin, Karapetyan Nune, Janoyan Naira, Badalyan Levon, Mailian Mariam, Geokchyan Haykuhi, Bardakhchyan Vardan, Baloyan Elen, Petrosyan Hasmik, Soghomonyan Karine, Tadevosyan Anna, Bedirian Karen, Hovsepyan Shushan, Bardakhchyan Samvel
Аннотация
PURPOSE: In Armenia, a lower-middle-income country, cancer causes 21% of all deaths, with over half of cases diagnosed at advanced stages. Without universal health insurance, patients rely on out-of-pocket payments or black-market channels for costly immunotherapies, underscoring the need for real-world data to inform equitable policy reforms.
METHODS: We conducted a multicenter, retrospective cohort study of patients who received at least one dose of an immune checkpoint inhibitor (ICI) between January 2017 and December 2023 across six Armenian oncology centers. Eligible patients had histologically confirmed malignancy and ≥6 months of follow-up. Demographic, clinical, biomarker, and treatment data were extracted from records. Overall survival (OS) was estimated by the Kaplan-Meier method; log-rank tests and Cox models evaluated associations. A 6-month landmark analysis adjusted for immortal time bias.
RESULTS: Of the 585 patients screened, 373 met inclusion criteria (67% male; median age, 61 years); 68% had stage IV disease. The median OS was 31 months. Liver metastases predicted poorer survival (19 v 26 months, P = .027). Nonsmokers had better OS than smokers (31 v 24 months, P = .019). High PD-L1 expression (≥50%) was associated with improved OS (40 v 16 months, P = .025). Receiving >6 ICI cycles conferred longer OS (45 v 23 months, P < .001), although not significant in landmark analysis (P = .64). Financial hardship and disease progression were key reasons for early discontinuation.
CONCLUSION: Immunotherapy shows promise in Armenia despite financial barriers. Drawing on models from India and China, pooled procurement, negotiated pricing, and partial reimbursement, Armenia could expand biomarker testing, reduce drug costs, and implement tiered insurance. These steps are vital to optimize access and outcomes in this resource-limited setting.
METHODS: We conducted a multicenter, retrospective cohort study of patients who received at least one dose of an immune checkpoint inhibitor (ICI) between January 2017 and December 2023 across six Armenian oncology centers. Eligible patients had histologically confirmed malignancy and ≥6 months of follow-up. Demographic, clinical, biomarker, and treatment data were extracted from records. Overall survival (OS) was estimated by the Kaplan-Meier method; log-rank tests and Cox models evaluated associations. A 6-month landmark analysis adjusted for immortal time bias.
RESULTS: Of the 585 patients screened, 373 met inclusion criteria (67% male; median age, 61 years); 68% had stage IV disease. The median OS was 31 months. Liver metastases predicted poorer survival (19 v 26 months, P = .027). Nonsmokers had better OS than smokers (31 v 24 months, P = .019). High PD-L1 expression (≥50%) was associated with improved OS (40 v 16 months, P = .025). Receiving >6 ICI cycles conferred longer OS (45 v 23 months, P < .001), although not significant in landmark analysis (P = .64). Financial hardship and disease progression were key reasons for early discontinuation.
CONCLUSION: Immunotherapy shows promise in Armenia despite financial barriers. Drawing on models from India and China, pooled procurement, negotiated pricing, and partial reimbursement, Armenia could expand biomarker testing, reduce drug costs, and implement tiered insurance. These steps are vital to optimize access and outcomes in this resource-limited setting.